Sustained reduction in pruritus seen with MRX in children with Alagille syndrome

Children with Alagille syndrome who received 48 weeks of Maralixibat had clinically meaningful reduction in pruritus and improvements in quality of life, according to a presentation at The Liver Meeting Digital Experience.Benjamin L. Shneider, MD, from the department of pediatrics and the division of pediatric gastroenterology, hepatology and nutrition at Baylor College of Medicine and Texas Children’s Hospital, said the changes persisted for 96 weeks in patients who continued to receive Maralixibat (MRX; Mirum Pharmaceuticals).“Initial data from the multi-institutional IMAGINE IIRead More

Share on facebook
Share on twitter
Share on linkedin